Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-18
2007-09-18
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S392000, C514S422000, C546S016000, C548S518000, C548S301400
Reexamination Certificate
active
10538134
ABSTRACT:
The present invention relates to compounds of formula (I), or pharmaceutically acceptable derivatives thereof, useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).
REFERENCES:
patent: 5861416 (1999-01-01), Burkholder et al.
patent: 5861417 (1999-01-01), Burkholder et al.
patent: WO9426735 (1994-11-01), None
STN search result of WO 94/26735, Burkholder et al., Nov. 1994, PCT.
Wikipedia for hetercyclic compound, on-line edition.
TYLE, Iontophoretic Devices for Drug Delivery, Pharmaceutical Research 3(6):318-326 (1986).
Aquino Christopher Joseph
Kazmierski Wieslaw Mieczyslaw
Yang Hanbiao
Anderson Rebecca
Chu Yong
Deppenbrock Bonnie L.
SmithKline Beecham Corporation
LandOfFree
Pyrrolidine and azetidine compounds as CCR5 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidine and azetidine compounds as CCR5 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine and azetidine compounds as CCR5 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3801211